Congress Materials - Rheumatology Advanced Practice Providers (RhAPP 2025)
2025 Rheumatology Advanced Practice Providers | Sep 25-27 | Denver, CO
Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primary Sjogren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study (DAHLIAS)
Jacques Eric Gottenberg, Kathy Sivils, Kim Campbell, Jada Idokogi, Kim Lo, Sophia G. Liva, Elizabeth Adamson, Harman Dhatt, Jonathan J. Hubbard, Ghaith Noaiseh
Efficacy and Safety of Subcutaneous Guselkumab Induction Therapy in Patients with Ulcerative Colitis: Results Through Week 24 from the Phase 3 ASTRO Study
Millie Long, Jessica R. Allegretti, Silvio Danese, Matthew Germinaro, Thomas Baker, Yelina Alvarez, Silke Jörgens, Lingjing Jiang, Hongyan Zhang, Melissa Petrick, Tadakazu Hisamatsu, David T. Rubin, Laurent Peyrin-Biroulet
Guselkumab for Treatment of Juvenile Psoriatic Arthritis: Data Extrapolation from Studies in Adjacent Adult and Pediatric Populations
Herta Crauwels, Sarah Ringold, Samantha Howard, Bart Van Hartingsveldt, Valerie Smith, Meg Jett, Tristan Baguet, Elizabeth Adamson, Soumya D. Chakravarty, Jocelyn H. Leu
Icotrokinra, a Novel Targeted Oral Peptide, in Patients with Psoriatic Disease: Exploratory Assessments from a Phase 2 Psoriasis Study Informing a Phase 3 Clinical Program in Psoriatic Arthritis
Joseph Merola, Philip Mease, Laura Coates, Iain McInnes, Peter Nash, Alexis Ogdie, Lihi Eder, Mitsumasa Kishimoto, Anna Beutler, Konstantina Psachoulia, Shana Hamm, Shihong Sheng, Bei Zhou, Mehrdad Javidi, Chandni Valiathan, Charles Iaconangelo, Ya-Wen Yang, Arun Kannan, Daniel Kakaley, Chetan Karyekar, Tasneam Shagroni
Inhibition of Structural Damage Progression with Guselkumab, a Selective IL-23i, in Participants with Active PsA: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study
Philip J. Mease, Christopher T. Ritchlin, Laura C. Coates, Alexa P. Kollmeier, Bei Zhou, Yusang Jiang, Karen Bensley, Koeun Im, Rattandeep Batra, Daniel Kakaley, Soumya D. Chakravarty, Proton Rahman, Désirée van der Heijde
Safety of Guselkumab in Inflammatory Bowel Disease Up to 1 Year: Integrated Safety Analysis of Phase 2 and 3 Studies in Crohn’s Disease and Ulcerative Colitis
Bruce E. Sands, Remo Panaccione, Silvio Danese, Julián Panés, Tadakazu Hisamatsu, Geert D’Haens, Rian Van Rampelbergh, Mobolaji Olurinde, Jacqueline Yee, Thomas Baker, Shadi Yarandi, Matthew Germinaro, Marion L. Vetter, Hewei Li, Melissa Petrick, Mauricio Rosas Ballina, Jessica R. Allegretti, Anita Afzali, David T. Rubin
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.